Dersimelagon

Erythropoietic protoporphyria and X-linked protoporphyria are inherited disorders of heme biosynthesis in which protoporphyrin IX accumulates and is photoactivated by visible light near 400 nm, producing severe non-blistering phototoxic pain within minutes of sunlight exposure. Estimated incidence is two to five per 1,000,000, and reported prevalence ranges from 1 in 75,000 in the Netherlands to 1 in 200,000 in Wales; X-linked protoporphyria accounts for about 10% of cases in the United States. Photosensitivity begins in infancy or childhood, with a mean age at symptom onset of 4.4 years, and persists for life. Most patients tolerate less than 30 minutes of sun exposure. In a survey of 164 adults and 33 adolescents, symptoms hindered daily activities at least somewhat for 62.8% of adults and 87.9% of adolescents. Hepatic dysfunction occurs in 20% to 30% of individuals and 2% to 5% develop severe liver disease; in a United States longitudinal study of 322 participants, 8 (2.5%) had a liver transplant and 8 (2.5%) died, with at least half of deaths attributable to liver involvement. In a national claims analysis of 696 patients, mean all-cause costs were $71,714 per patient per year compared with $18,646 in matched comparators.

Dersimelagon is an oral selective melanocortin 1 receptor agonist that increases eumelanin production. Three randomized placebo-controlled trials have been completed in these disorders. The phase 2 ENDEAVOR trial randomized 102 adults to placebo or dersimelagon 100 mg or 300 mg once daily; the least-squares mean difference from placebo in change from baseline to week 16 in average daily time to first prodromal symptom was 53.8 minutes at 100 mg (P = 0.008) and 62.5 minutes at 300 mg (P = 0.003). The first phase 3 trial, MT-7117-G01, randomized 184 adults and adolescents to two undisclosed doses or placebo and did not meet its primary endpoint at week 26: the least-squares mean difference from placebo was 9.8 minutes at the low dose (95% confidence interval -18.52 to 38.12; P = 0.496) and 22.7 minutes at the high dose (95% confidence interval -5.68 to 51.09; P = 0.116). Because sequential testing stopped at that point, all secondary P values from that trial are nominal. The second phase 3 trial, INSPIRE, randomized 165 participants aged 12 to 75 years, 82 to dersimelagon 200 mg once daily and 83 to placebo, and met its primary endpoint over weeks 12 to 16 with a placebo-adjusted least-squares mean difference of 23.19 minutes (P = 0.004); the presenter reported that time to prodrome was similar between groups at week 16 alone. Patient Global Impression of Change differed by -1.83 points (P < 0.001) and total pain events were 39% lower (P = 0.004). No INSPIRE results have been posted to any registry and no peer-reviewed publication exists. Reported adverse events across the program are consistent with the mechanism and include melanocytic nevi, skin hyperpigmentation, nausea, headache, and diarrhea. One death occurred, from cholestasis in the high-dose arm of MT-7117-G01, assessed as probably related by the investigator and unlikely or unrelated by the sponsor. One serious treatment-emergent adverse event in INSPIRE was a malignant melanoma in situ identified on day 36 in a participant with a family history of melanoma and a pre-existing lesion.

No product-specific budget impact model, cost-effectiveness analysis, or health technology assessment of dersimelagon exists, and no United States wholesale acquisition cost or average sales price has been announced. The United Kingdom horizon-scanning briefing recorded the cost as confidential. The Dutch horizon scan gives an expected cost of €71,000 per patient per year, which that source states is derived from the median cost of medicines in Anatomical Therapeutic Chemical class D02BB in the Netherlands rather than from a manufacturer price. The payer record for afamelanotide, the only approved therapy, is mixed: the National Institute for Health and Care Excellence did not recommend it, with evidence review group estimates from £133,748 to £1,958,162 per quality-adjusted life year gained at a stated implant cost of £13,209 excluding value added tax; Germany accepted an annual cost of €51,875.85 to €69,167.80; Norway declined funding; and the Netherlands and Scotland recommended access. Current treated prevalence is low, with 7.6% of claims-identified patients in the United States receiving any treatment and 3.9% receiving afamelanotide.

The Food and Drug Administration accepted the dersimelagon New Drug Application for filing with Priority Review, with a Prescription Drug User Fee Act action date by the end of February 2027. The product is not approved in any jurisdiction. If approved, it would be the first oral therapy for these disorders and the first available to patients aged 12 to 17 years. The application rests on one positive phase 3 trial, INSPIRE, for which no registry results, protocol, statistical analysis plan, confidence intervals, disposition table, or baseline characteristics have been published, and which is preceded by a larger and longer phase 3 trial that did not meet the same primary endpoint. The measured effect in INSPIRE, 23.19 minutes of additional daily sunlight exposure before the first prodromal symptom over weeks 12 to 16, is smaller than the 53.8 to 62.5 minutes observed in the phase 2 trial and was not significant at the registered week 16 timepoint. Because the drug produces visible pigmentation, blinding was incomplete in the phase 2 trial, where 97% to 100% of actively treated participants correctly identified their assignment. Two safety observations warrant attention for a chronic therapy in this class: a 20.7% rate of melanocytic nevi compared with 1.2% on placebo in INSPIRE with one malignant melanoma in situ, and the hepatobiliary signal from the earlier phase 3 trial, which included one fatal cholestasis. No United States price, budget impact model, or head-to-head comparison against afamelanotide exists.